Journal Articles
2020

Time to Develop Therapeutic Antibodies Against Harmless
Proteins Colluding with Sepsis Mediators?
J. Li
G. Bao
H. Wang
Zucker School of Medicine at Hofstra/Northwell, hwang@northwell.edu

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Emergency Medicine Commons

Recommended Citation
Li J, Bao G, Wang H. Time to Develop Therapeutic Antibodies Against Harmless Proteins Colluding with
Sepsis Mediators?. . 2020 Jan 01; 9():Article 7112 [ p.]. Available from:
https://academicworks.medicine.hofstra.edu/articles/7112. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

ImmunoTargets and Therapy

Dovepress
open access to scientific and medical research

Open Access Full Text Article

REVIEW

Time to Develop Therapeutic Antibodies Against
Harmless Proteins Colluding with Sepsis
Mediators?
This article was published in the following Dove Press journal:
ImmunoTargets and Therapy

Jianhua Li 1, *
Guoqiang Bao 2, *
Haichao Wang 1,3
1

The Feinstein Institutes for Medical
Research, Northwell Health, Manhasset,
NY 11030, USA; 2Department of General
Surgery, Tangdu Hospital, Xi’an, Shaanxi
710032, People’s Republic of China;
3
Donald and Barbara Zucker School of
Medicine at Hofstra/Northwell,
Hempstead, NY 11549, USA
*These authors contributed equally to
this work

Abstract: Sepsis refers to a systemic inflammatory response syndrome resulting from
microbial infections, and is partly attributable to dysregulated inflammation and associated
immunosuppression. A ubiquitous nuclear protein, HMGB1, is secreted by activated leuko
cytes to orchestrate inflammatory responses during early stages of sepsis. When it is released
by injured somatic cells at overwhelmingly higher quantities, HMGB1 may induce macro
phage pyroptosis and immunosuppression, thereby impairing the host’s ability to eradicate
microbial infections. A number of endogenous proteins have been shown to bind HMGB1 to
modulate its extracellular functions. Here, we discuss an emerging possibility to develop
therapeutic antibodies against harmless proteins that collude with pathogenic mediators for
the clinical management of human sepsis and other inflammatory diseases.
Keywords: antibody, HMGB1, immunosuppression, inflammation, innate immune cells,
pyroptosis, sepsis
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Cohabitating with microbes, mammals employ epithelial barriers as the first layer
of defense to limit the access of many pathogens. If they are breached, the host
mounts an immediate immune response termed “inflammation” (“set on fire” in
Greek) to eliminate these invading pathogens.1 For instance, circulating monocytes
are ceaselessly patrolling the body to search for invading pathogens, and immedi
ately infiltrate into the infected tissues upon detecting microbial products.2 Once
reaching extravascular tissues, these monocytes are terminally differentiated into
tissue-specific resident macrophages, which ingest and eradicate pathogens together
with neutrophils and other phagocytes.3
Meanwhile, macrophages/monocytes are also equipped with Pattern
Recognition Receptors [PRR, such as the Toll-like Receptor 2 (TLR2), TLR3,
TLR4 and TLR9] that can bind distinct Pathogen-Associated Molecular Patterns
molecules (PAMPs, such as bacterial peptidoglycan, double-stranded RNA, endo
toxin and CpG-DNA).4,5 The engagement of PAMPs with respective PRRs triggers
the immediate release of tumor necrosis factor (TNF),6 interleukin (IL)-1,7 and
interferon (IFN)-α,8 which collectively facilitate pathogen elimination. If unsuc
cessful, invading pathogens can leak into the bloodstream to trigger a systemic
inflammatory response and life-threatening organ dysfunction termed “sepsis”.9
The pathogenesis of sepsis is complex but attributable to dysregulated inflammatory
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responses and immunosuppression. 10−12 For instance,
neutralizing antibodies against TNF, the first cytokine ela
borated in the inflammatory cascade, were protective in
animal models of endotoxemic/bacteremic shock.6
However, the early release of TNF makes it difficult to
target in clinical settings,13 prompting the search for other
late mediators with wider therapeutic windows.

High Mobility Group Box 1 (HMGB1)
High mobility group 1 (HMG-1) was initially identified as a
30-kDa protein with a high mobility on electrophoresis gels,14
and recently renamed as the high mobility group box-1
(HMGB1).15 It contains a continuous stretch of negatively
charged residues in the C-terminus, and two internal repeats
of positively charged domains (“HMG boxes” known as “A
box” and “B box”) in the N-terminus (Figure 1).16 These
HMG boxes enable HMGB1 to bind chromosomal DNA to
fulfill its nuclear functions in stabilizing nucleosomal structure
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Figure 1 Pathogen-Associated Molecular Pattern molecules (PAMPs) trigger
HMGB1 release through inducing pyroptosis or necroptosis.

158

submit your manuscript | www.dovepress.com

DovePress

and stability, and facilitating the binding of transcription fac
tors to their cognate DNA sequences during gene expression.
16,17
Conditional knockout of HMGB1 expression renders
animals more susceptible to both infectious18 and injurious
insults,19,20 supporting a beneficial role of intracellular
HMGB1 in health.

Secretion by Activated Macrophages/
Monocytes
Two decades ago, we initiated an effort to search for late
mediators that could contribute to the pathogenesis of lethal
sepsis. Specifically, we stimulated macrophage cultures with
an early cytokine (eg, TNF) and screened the cell-conditioned
medium for proteins that were released relatively late. This
effort led to the identification of 30-kDa protein with an
N-terminal amino acid sequence identical to HMG-1
(HMGB1).15,21 Subsequently, we and others demonstrated
that many exogenous PAMPs (eg, ds-RNA, CpG-DNA and
endotoxins)21,22 and endogenous cytokines [eg, interferon
(IFN)-γ, IFN-β, serum amyloid A (SAA), and Cold-inducible
RNA-binding protein (CIRP)]23–26 similarly induced HMGB1
translocation to cytoplasmic vesicles.23,27–30 Consequently,
these activated macrophages/monocytes secrete cytoplasmic
HMGB1 vesicles via non-classical endoplasmic reticulumGolgi exocytotic pathways.21,23,27–30

Release by Injured Somatic Cells
In addition, HMGB1 can be passively released by somatic
cells undergoing cytoplasmic membrane destruction due to
accidental (mechanical or chemical) events or regulated pro
cesses governed by specific caspases or kinases. For instance,
many PAMPs induce a form of programmed necrosis, pyrop
tosis (Figure 1),31 that is characterized by the oligomerization
of the apoptosis-associated speck-like protein containing a
C-terminal caspase recruitment domain (ASC) and its integra
tion with pro-caspase-1 and a NOD-Like Receptor (eg,
NLRP3) to form a large inflammasome complex (pyropto
some) that eventually disrupts cytoplasmic membranes.32,33
Similarly, many proinflammatory cytokines (eg, TNF and
IFN-γ) induce another form of programmed necrosis (necrop
tosis) via activating protein kinase receptor-interacting protein
3 (RIP3) and the interferon-induced double-stranded RNAactivated protein kinase R (PKR) (Figure 1).34–36 Collectively,
pyroptosis33,37 and necroptosis38 allow passive HMGB1
release following ischemia/reperfusion,39,40 non-penetrating
trauma,41,42 chemical toxemia,43 or radiation,44 leading to
massive HMGB1 release during lethal infections and injuries.
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Extracellular HMGB1 and Innate
Immunity
Extracellular HMGB1 binds many cell surface receptors
such as the TLR445–47 and the receptor for advanced
glycation end products (RAGE) (Figure 2).48–51 Due to
its dramatically (4–30-fold) different affinities to TLR4/
MD2 (KD = 22.0 nM)47 and RAGE (KD = 97.7–710
nM),48,49 HMGB1 may first bind TLR4/MD2 when it is
actively secreted by innate immune cells at relatively
lower amount.52 However, when it is passively released
by somatic cells at relatively higher levels, HMGB1 may
also bind RAGE48,50,53 and other low-affinity receptors.
Like TLR4,4,45–47 RAGE also recognizes many other
ligands including the advanced glycation end-products
(AGEs), complement component (eg, C1q, KD = 5.6
µM) or endotoxins (KD = 2–35 nM).51 Thus, HMGB1
may orchestrate divergent inflammatory responses through
activating different PRRs interacting with a wide array of
inflammatory ligands.

Extracellular HMGB1 Amplifies
Inflammation
First, as a highly charged molecule, HMGB1 binds and facil
itates the cellular uptake of negatively charged PAMPS (eg,
CpG-DNA and LPS) via RAGE-receptor-mediated
endocytosis.53 Upon reaching acidic endosomal and lysoso
mal compartments near HMGB1’s isoelectric pH, HMGB1
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Figure 2 Extracellular HMGB1 induces divergent inflammatory responses through
different receptors. Note that RAGE is involved in HMGB1 endocytosis and induc
tion of leukocyte pyroptosis and possible immunosuppression due to immune cell
depletion.
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becomes neutrally charged and sets free its cargos,53 thereby
facilitating their recognition by respective receptors such as
TLR954 or caspase-11 53. Second, the engagement of RAGE
with HMGB1 also induces chemotaxis55 and the migration of
monocytes, dendritic cells56,57 and neutrophils,58 thereby facil
itating the recruitment of innate immune cells to the sites of
infection and injury (Figure 2).55 Third, HMGB1 can even
directly activate macrophages59 and endothelial cells60 to pro
duce various cytokines and chemokines,45,46,60–63 thereby sus
taining a dysregulated inflammatory responses during
infections (Figure 2).64 Thus, extracellular HMGB1 functions
as an alarmin signal to alert, recruit and activate immune cells,
thereby amplifying inflammatory responses.
Following traumatic injury, HMGB1 is detected in the
circulation within a few hours,41,42,65 and its systemic levels
correlated with post-traumatic inflammatory responses41,66
and worsening clinical scores.67 Accordingly, HMGB1-neu
tralizing antibodies have been proven protective in animal
models of ischemia/reperfusion,39,68,69 trauma,70,71 chemical
toxemia,72–74 atherosclerosis,75 gastric ulcer,76 and
hyperoxia,77 supporting a pathogenic role of HMGB1 in
injury-elicited inflammatory diseases.

Extracellular HMGB1 Induces
Immunosuppression
It is well known that antecedent traumatic injury often
dampens subsequent innate immunity against secondary
infections, suggesting a possible pathogenic role of
DAMP in immune tolerance or immunosuppression. As
aforementioned, when HMGB1 is passively released by
damaged tissues at overwhelmingly high levels, it can bind
RAGE48–50,78 to induce TLR4 internalization and desensi
tization to subsequent stimulation with inflammatory
ligands (eg, endotoxin). Furthermore, at relatively higher
doses (eg, 10 µg/mL), HMGB1 could also binds RAGE to
trigger macrophage pyroptosis,53,79 apoptosis80 and
necrosis,80 resulting in possible depletion of innate
immune cells and immunosuppression (Figure 2).
Therefore, excessive HMGB1 accumulation may induce
immune tolerance81,82 as well as immunosuppression83
that compromises the host’s ability to eradicate microbial
infections during lethal injuries and infections.84,85

HMGB1 as a Late Mediator of
Lethal Sepsis
In preclinical settings, sepsis is routinely induced by the
infusion of bacterial endotoxins (endotoxemia) or the
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disruption of host epithelial barrier to induce microbial
translocation by a surgical procedure termed cecal ligation
and puncture (CLP).86 In murine models of endotoxemia
and CLP-sepsis, HMGB1 is first detected in the circulation
8 hours after the disease onset, and subsequently increased
to plateau levels from 16 to 32 hours,21,87 distinguishing
HMGB1 from TNF and other early proinflammatory
cytokines.13 The pathogenesis of HMGB1 in endotoxemia
was inferred from studies using HMGB1-neutralizing anti
bodies, which conferred a dose-dependent protection
against endotoxin-induced tissue injury and lethality.21,88
Intriguingly, anti-HMGB1 antibodies did not affect endo
toxin-induced cytokine production in the lung inflamma
tion model, suggesting that HMGB1 may contribute to
lung injury through additional inflammation-independent
mechanisms.88 Indeed, it has been shown that excessive
HMGB1 accumulation in the bronchoalveolar space
adversely compromised bacteria-killing capacities of
alveolar macrophages,77 which were similarly reversed
by HMGB1-neutralizing antibodies.89
In a more clinically relevant animal model of sepsis
(induced by CLP), delayed administration of HMGB1-spe
cific neutralizing antibodies, beginning 24 h after CLP,
dose-dependently rescued rodents from lethal sepsis.87,90,91
Moreover, targeted inhibition of HMGB1 expression in
macrophages and dendritic cells reduced systemic
HMGB1 accumulation, and similarly rescued mice from
sepsis.92 Taken together, these experimental data establish
extracellular HMGB1 as a critical late mediator of experi
mental sepsis, which can be therapeutically targeted with
wider
therapeutic
windows
than
other
early
cytokines.1,13,93,94

Endogenous HMGB1-Binding
Proteins
To prevent potentially harmful inflammatory responses,
mammals have also developed many strategies to coun
ter-regulate HMGB1-mediated cytokine productions. For
instance, an endothelial anticoagulant cofactor, thrombo
modulin (TM), could bind HMGB1 to prevent its interac
tion with macrophage cell surface receptors,95 thereby
preventing HMGB1-induced inflammatory response.96,97
Similarly, a liver-derived acute-phase protein, haptoglobin
(Hp), could capture HMGB1 to trigger CD163-dependent
endocytosis of HMGB1/Hp complexes, and instead
induced the production of anti-inflammatory enzymes
(heme oxygenase-1) and cytokines (eg, IL-10).98
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Moreover, a complement factor C1q also interacted with
HMGB1 (KD = 200 nM) and formed a tetramolecular
complex with RAGE and LAIR-1, resulting in the produc
tion of anti-inflammatory cytokines (eg, IL-10) and proresolution lipid mediators.99,100 Thus, in a sharp contrast to
exogenous PAMPs (eg, CpG-DNA and LPS), many endo
genous proteins can bind HMGB1 to tilt the balance
towards anti-inflammatory responses via distinct signaling
pathways.95,98–100

Development of Antibodies Against
an Endogenous Protein
(Tetranectin, TN) Colluding with
HMGB1
Tetranectin (TN) was initially characterized as an oligo
meric plasminogen-binding protein101 exhibiting >75%
amino acid sequence identity between humans and
rodents.102 It is expressed abundantly in the lung103 but
also present at relatively high levels (10–12 µg/mL) in the
bloodstream of healthy humans 104. In rodents, enhanced
expression or genetic depletion of TN led to abnormal
osteogenesis 105, excessive curvature of the thoracic
spine-spinal deformity,106 deficient motor function (such
as limb rigidity),107 or impaired wound healing,108,109
suggesting a generally beneficial role of TN in health.

TN Depletion in Sepsis
While searching for endogenous proteins modulating
HMGB1 release, we noticed that the blood level of a 20kDa protein was almost completely depleted in a patient
who died of sepsis. This 20-kDa protein was identified as
human TN by mass spectrometry and immunoblotting
assays.110 Further analysis of a cohort of 44–45 agematched healthy controls and critically ill patients revealed
a 60–70% reduction of plasma TN levels in patients with
sepsis or septic shock. In accordance with these clinical
findings, circulating TN levels were similarly decreased in
experimental sepsis, with a >70% reduction at 24 h after
disease onset— a time point when some septic animals
started to lose survival.110

Surprising Discovery of TN-Specific
Protective Antibodies
To understand the role of TN in sepsis, we would normally
perform three sets of experiments to find out what would
happen if we: 1) genetically knocked out its expression; 2)
pharmacologically supplemented septic animals with
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recombinant TN protein; and 3) treated septic animals with
TN-specific antibodies? First, genetic disruption of TN
expression rendered animals more susceptible to lethal
sepsis with exacerbated lung inflammation and injury,
suggesting a protective role of TN in sepsis.110
Conversely, supplementation of sub-physiological dose of
TN at 2 and 24 h after the onset of lethal sepsis conferred a
dose-dependent protection, further confirming its protec
tive role in disease. Surprisingly, when we treated septic
animals with polyclonal antibodies (pAbs) generated in
four rabbits, we found that total IgGs purified from two
rabbits reproducibly reduced septic lethality even when the
first dose was given 22 h after CLP.110
Screening a library of peptides spanning the entire
sequence of human TN revealed that these two protective
pAbs uniquely recognized a peptide (P5) harboring an
epitope sequence (NDALYEYLRQ, “P5-5”) exhibiting
60–70% identity between humans and rodents, but a
100% identity between humans and many other mamma
lian species (ranging from pigs to monkeys). We thus
strategically immunized mice with human TN antigen
and generated several hybridoma clones producing P5-5reactive monoclonal antibodies (mAbs). When adminis
tered to septic mice 24 h after CLP, three P5-5-reacting
mAbs similarly and significantly rescued mice from lethal
sepsis by attenuating sepsis-induced TN depletion, tissue
injury, as well as bacteremia.110 It suggests a possibility
that TN domain-specific mAbs conferred protection
against lethal sepsis partly by facilitating pathogen
elimination.

TN Interacts with HMGB1 to Facilitate
HMGB1 Endocytosis and Macrophage
Pyroptosis
Intriguingly, highly purified TN protein selectively inhib
ited the LPS- and SAA-induced HMGB1 release without
affecting the parallel release of other cytokines and chemo
kines. This selective inhibition of HMGB1 release was
attributable to TN’s capacity in capturing HMGB1 and
facilitating the endocytosis of TN/HMGB1 complexes by
macrophage cultures (Figure 3).110 Consistent with pre
vious findings that HMGB1 endocytosis triggered macro
phage pyroptosis,53,79 we found that TN enhanced
HMGB1-induced translocation of nuclear ASC to cytoplas
mic regions, where ASC either aggregated into minute
puncta that appeared to be secreted through microvesicle
shedding, or aggregated into a larger focus or speck
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(pyroptosome) that would trigger pyroptosis.110
Consequently, TN significantly enhanced HMGB1-induced
uptake of trypan blue dye and parallel release of LDH and
ASC, a marker for macrophage pyroptosis.111 Taken
together, these findings suggest that TN could capture
HMGB1 released into the circulation during sepsis, thereby
promoting HMGB1 endocytosis and macrophage pyropto
sis, leading to possible immunosuppression that may com
promise effective pathogen elimination (Figure 3).

TN-Specific mAbs Prevent Harmful TN/
HMGB1 Interaction and Macrophage
Pyroptosis
To understand the protective mechanism of TN domainspecific mAbs, we tested their possibility in disrupting TN/
HMGB1 interaction using the Surface Plasmon Resonance
technique. When the TN-conjugated sensor chip was pretreated with mAb, the SPR response signal for subsequent
HMGB1 application was reduced by >85%, which was
paralleled by an almost 6-fold increase of KD, indicating
that these TN domain-specific protective mAbs effectively
interrupted TN/HMGB1 interaction (Figure 3).110
Furthermore, these protective mAb markedly prevented
the reciprocal enhancement of cellular uptake of HMGB1
and TN, and prevented the TN/HMGB1-induced cytoplas
mic ASC translocation or aggregation into large ASC
specks in macrophage cultures. It suggests a possibility
that TN domain-specific mAbs may confer protection
against lethal sepsis partly by preventing harmful TN/
HMGB1 interaction that may adversely trigger macro
phage pyroptosis and immunosuppression (Figure 3).

Conclusion
Sepsis remains a major clinical problem that accounts for
approximately 20% of total deaths worldwide,112 and
annually costs more than $62 billion in the US alone.113
Despite a robust increase in the understanding of the patho
physiology of sepsis, many antibody-based strategies target
ing early pro-inflammatory cytokines (such as TNF or IL-1)
failed in clinical settings. Currently, there is still no effective
therapy114 other than adjunctive use of antibiotics, fluid
resuscitation, and supportive care.113 By using a bedside to
bench approach, we have identified additional unexpected
biological targets with potential translational promise. The
interaction of a harmless protein (TN) with a pathogenic
mediator (HMGB1) released into the circulation during sep
sis adversely promoted HMGB1 endocytosis and
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Figure 3 Proposed model for tetranectin domain-specific monoclonal antibody (mAb)-mediated protection against lethal sepsis. Severe microbial infections cause systemic
accumulation of HMGB1 and concurrent depletion of TN, partly because circulating HMGB1 binds to TN to facilitate the endocytosis and degradation of TN/HMGB1
complexes by innate immune cells. The endocytosis of TN/HMGB1 complex also adversely triggers macrophage pyroptosis and immunosuppression that may compromise
effective pathogen elimination and animal survival. Some TN-reactive mAbs, such as mAb8, could bind to specific epitope sequence (NDALYEYLRQ) of TN to interrupt its
interaction with HMGB1, thereby impairing HMGB1 endocytosis and macrophage pyroptosis, and consequently reversing the sepsis-induced immunosuppression and animal
lethality.

macrophage pyroptosis (Figure 3), which triggers both
excessive inflammation and ineffective pathogen elimination
in a feed-forward mechanism ultimately leading to host
lethality.114 Although pyroptosis normally serves as a host
defense mechanism against infection,115 it could also allow
the excessive release of HMGB1 and other proinflammatory
cytokines (eg, IL-1β) that adversely drive a life-threatening
inflammatory response.114 Meanwhile, excessive pyroptosis
also depletes the number of innate immune cells necessary
for pathogen clearance, resulting in a possible immunosup
pression (Figure 3).
An antibody that interferes with TN/HMGB1 interac
tion thus represents a rational therapeutic approach to
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prevent macrophage cell death and resultant sequelae.
Our recent discovery of several TN-specific mAbs capable
of recognizing a highly conserved epitope sequence
(NDALYEYLRQ) in humans and many mammalian spe
cies (including baboon, bovine, cougar, elephant, monkey,
pig and tiger) has suggested a promising therapy for sepsis
in clinical settings. At present, it remains elusive whether
these TN-specific mAbs also attenuate HMGB1-induced
apoptosis or necrosis that are similarly associated with
poor outcomes in preclinical settings. It is also not yet
known whether TN-specific mAbs similarly affect TN
interaction with other proteins (for example, plasminogen)
that may affect sepsis-induced dysregulated coagulopathy.
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Finally, given the pathogenic role of HMGB1 in injuryelicited inflammatory diseases, the role of TN in other
inflammatory diseases should also be explored.114
Thus, it would be exciting to translate these pre-clinical
findings into clinical applications through the use of huma
nized TN-specific mAbs capable of preventing its undesired
interaction with pathogenic mediators that could cause macro
phage pyroptosis and immunosuppression during lethal infec
tions or injuries.110 Moreover, the discovery of mAbs capable
of disrupting TN/HMGB1 interaction and endocytosis and
rescuing animals from lethal sepsis has suggested an exciting
possibility to develop therapeutic antibodies against harmless
proteins colluding with disease mediators.
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